NHS National Proprietary Pharmaceuticals - Low Molecular Weight Heparins and Fondaparinux Products
Estimated value
—
Awarded value
£321.3m
Awarded 28 Nov 2025
Suppliers
8
3 SME
Lots
1
1 awarded
Published
28 Nov 2025
Description
NHS National Proprietary Pharmaceuticals – Low Molecular Weight Heparins and Fondaparinux Products – CM/PHR/22/5732 Period of Framework Agreement: 1 March 2026 to 29 February 2028 with an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Scope
- Reference
- C381280
- Commercial tool
- Standalone contract
- Contract dates
- 01 Mar 2026 to 29 Feb 2028Possible extension to 28 Feb 2030
With an option or option(s) to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
- CPV classifications
- 33600000
- Contract locations
- North East England, United KingdomNorth West England, United KingdomEast Midlands, United KingdomWest Midlands, United KingdomEast of England, United KingdomLondon, United KingdomSouth East England, United KingdomSouth West England, United KingdomYorkshire and the Humber, United Kingdom
- Particular suitability
- Small and medium-sized enterprises (SME)
Award criteria
Criteria the buyer will use to evaluate bids.
| Name | Description | Type | Weighting |
|---|---|---|---|
| Price is not the only award criterion | Price is not the only award criterion and all criteria are stated only in the procurement documents | price | — |
Submission & procedure
- Procedure
- Open procedure
Award details
Awarded supplier(s), contract period and value as published in the award notice.
Awarded value
£321.3m
Award date
28 Nov 2025
Contract start
01 Mar 2026
Contract end
29 Feb 2028